Virginia F Borges1, Cristiano Ferrario2, Nathalie Aucoin3, Carla Falkson4, Qamar Khan5, Ian Krop6, Stephen Welch7, Alison Conlin8, Jorge Chaves9, Philippe L Bedard10, Marc Chamberlain11, Todd Gray11, Alex Vo11, Erika Hamilton12. 1. University of Colorado Denver, Aurora. 2. Jewish General Hospital, Montreal, Quebec, Canada. 3. Cite de la Sante de Laval, Laval, Quebec, Canada. 4. University of Alabama Comprehensive Cancer Center, Birmingham. 5. Kansas University Medical Center, Kansas City. 6. Dana-Farber Cancer Institute, Boston, Massachusetts. 7. London Health Science Center, London, Ontario, Canada. 8. Providence Cancer Center, Portland, Oregon. 9. Northwest Medical Specialties, Tacoma, Washington. 10. Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 11. Cascadian Therapeutics, Inc, Seattle, Washington. 12. Tennessee Oncology (SCRI), Nashville.
Abstract
Importance: Treatment options for patients with disease progression after treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) are limited. Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed as a novel treatment for ERBB2/HER2-positive breast cancer. Objective: To determine the maximum tolerated dosage of tucatinib in combination with T-DM1 in the treatment of patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases. Design, Setting, and Participants: In this phase 1b open-label, multicenter, clinical trial, 57 participants enrolled between January 22, 2014, and June 22, 2015, were 18 years of age or older with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Data were analyzed between January and March 2018. Interventions: Tucatinib 300 mg or 350 mg administered orally twice per day for 21 days and T-DM1 3.6 mg/kg administered intravenously once every 21 days. Main Outcomes and Measures: Safety assessments, pharmacokinetics, and response were assessed using RECIST 1.1 every 2 cycles for 6 cycles, followed by every 3 cycles. Results: Fifty-seven T-DM1-naive patients (median [IQR] 51 [44.0-63.0] years of age) who had undergone a median of 2 earlier HER2 therapies (range, 1-3) were treated. The tucatinib maximum tolerated dosage was determined to be 300 mg administered twice per day with dose-limiting toxic reactions seen at 350 mg twice per day. Pharmacokinetic analysis showed that there was no drug-drug interaction with T-DM1. Adverse events seen among the 50 patients treated at the maximum tolerated dosage regardless of causality included nausea (36 patients; 72%), diarrhea (30 patients; 60%), fatigue (28 patients; 56%), epistaxis (22 patients; 44%), headache (22 patients; 44%), vomiting (21 patients; 42%), constipation (21 patients; 42%), and decreased appetite (20 patients; 40%); the majority of adverse events were grade 1 or 2. Tucatinib-related toxic reactions that were grade 3 and above included thrombocytopenia (7 patients; 14%) and hepatic transaminitis (6 patients; 12%). Conclusions and Relevance: In this study, tucatinib in combination with T-DM1 appeared to have acceptable toxicity and to show preliminary antitumor activity among heavily pretreated patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases. Trial Registration: ClinicalTrials.gov Identifier: NCT01983501.
Importance: Treatment options for patients with disease progression after treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) are limited. Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed as a novel treatment for ERBB2/HER2-positive breast cancer. Objective: To determine the maximum tolerated dosage of tucatinib in combination with T-DM1 in the treatment of patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases. Design, Setting, and Participants: In this phase 1b open-label, multicenter, clinical trial, 57 participants enrolled between January 22, 2014, and June 22, 2015, were 18 years of age or older with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Data were analyzed between January and March 2018. Interventions: Tucatinib 300 mg or 350 mg administered orally twice per day for 21 days and T-DM1 3.6 mg/kg administered intravenously once every 21 days. Main Outcomes and Measures: Safety assessments, pharmacokinetics, and response were assessed using RECIST 1.1 every 2 cycles for 6 cycles, followed by every 3 cycles. Results: Fifty-seven T-DM1-naive patients (median [IQR] 51 [44.0-63.0] years of age) who had undergone a median of 2 earlier HER2 therapies (range, 1-3) were treated. The tucatinib maximum tolerated dosage was determined to be 300 mg administered twice per day with dose-limiting toxic reactions seen at 350 mg twice per day. Pharmacokinetic analysis showed that there was no drug-drug interaction with T-DM1. Adverse events seen among the 50 patients treated at the maximum tolerated dosage regardless of causality included nausea (36 patients; 72%), diarrhea (30 patients; 60%), fatigue (28 patients; 56%), epistaxis (22 patients; 44%), headache (22 patients; 44%), vomiting (21 patients; 42%), constipation (21 patients; 42%), and decreased appetite (20 patients; 40%); the majority of adverse events were grade 1 or 2. Tucatinib-related toxic reactions that were grade 3 and above included thrombocytopenia (7 patients; 14%) and hepatic transaminitis (6 patients; 12%). Conclusions and Relevance: In this study, tucatinib in combination with T-DM1 appeared to have acceptable toxicity and to show preliminary antitumor activity among heavily pretreated patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases. Trial Registration: ClinicalTrials.gov Identifier: NCT01983501.
Authors: Nancy U Lin; Eudocia Q Lee; Hidefumi Aoyama; Igor J Barani; Daniel P Barboriak; Brigitta G Baumert; Martin Bendszus; Paul D Brown; D Ross Camidge; Susan M Chang; Janet Dancey; Elisabeth G E de Vries; Laurie E Gaspar; Gordon J Harris; F Stephen Hodi; Steven N Kalkanis; Mark E Linskey; David R Macdonald; Kim Margolin; Minesh P Mehta; David Schiff; Riccardo Soffietti; John H Suh; Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen Journal: Lancet Oncol Date: 2015-05-27 Impact factor: 41.316
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: Véronique Diéras; David Miles; Sunil Verma; Mark Pegram; Manfred Welslau; José Baselga; Ian E Krop; Kim Blackwell; Silke Hoersch; Jin Xu; Marjorie Green; Luca Gianni Journal: Lancet Oncol Date: 2017-05-16 Impact factor: 41.316
Authors: Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531
Authors: Sandhya Girish; Manish Gupta; Bei Wang; Dan Lu; Ian E Krop; Charles L Vogel; Howard A Burris Iii; Patricia M LoRusso; Joo-Hee Yi; Ola Saad; Barbara Tong; Yu-Waye Chu; Scott Holden; Amita Joshi Journal: Cancer Chemother Pharmacol Date: 2012-01-20 Impact factor: 3.333
Authors: Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed Journal: Breast Cancer Res Treat Date: 2019-06-17 Impact factor: 4.872
Authors: Elena Shagisultanova; Lyndsey S Crump; Michelle Borakove; Jessica K Hall; Aryana R Rasti; Benjamin A Harrison; Peter Kabos; Traci R Lyons; Virginia F Borges Journal: Mol Cancer Ther Date: 2021-11-02 Impact factor: 6.261